Share on LinkedInShare on LinkedIn

ARTICLE · 11 APRIL 2019

Third time lucky - Insights from three extension of term applications for related pharmaceutical patents

These APO patent decisions provide guidance on the requirements and potential pitfalls when seeking an extension of term.

AustraliaIntellectual Property

Following on from our earlier article on patent term extension (PTE) for pharmaceutical substances, three related decisions issued by the Australian Patent Office provide guidance on the requirements and potential pitfalls when seeking an extension of term.

Criteria for eligibility and necessary document

As noted in our previous article, as set out by section 70 of the Patents Act 1990, a patent is eligible for PTE i) where the claims of the patent encompass:

  1. Pharmaceutical substance(s) per se; or
  2. Pharmaceutical substance(s) produced by recombinant DNA technology

and ii) where that pharmaceutical substance is included in goods which have received regulatory approval at least five years following the effective date of the patent.  The PTE application must be made in the "prescribed manner" which includes providing evidence to show that the goods containing the substance are currently included in the Australian Register of Therapeutic Goods (ARTG) and

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from